• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

作者信息

Braal C Louwrens, Beijnen Jos H, Koolen Stijn L W, Oomen-de Hoop Esther, Steeghs Neeltje, Jager Agnes, Huitema Alwin D R, Mathijssen Ron H J

机构信息

C. Louwrens Braal, PharmD, Erasmus University Medical Center, Rotterdam, the Netherlands; Jos H. Beijnen, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands, and Utrecht University, Utrecht, the Netherlands; Stijn L.W. Koolen, PhD, PharmD and Esther Oomen-de Hoop, PhD, Erasmus University Medical Center, Rotterdam, the Netherlands; Neeltje Steeghs, MD, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Agnes Jager, MD, PhD, Erasmus University Medical Center, Rotterdam, the Netherlands; Alwin D.R. Huitema, PharmD, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands, and Utrecht University, Utrecht, the Netherlands; and Ron H.J. Mathijssen, MD, PhD, Erasmus University Medical Center, Rotterdam, the Netherlands.

出版信息

J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18.

DOI:10.1200/JCO.19.00418
PMID:31211599
Abstract
摘要

相似文献

1
Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.4-羟基他莫昔芬浓度的相关性：缺乏证据并非没有证据。
J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18.
2
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.他莫昔芬的药物遗传学和代谢：来自前瞻性 CYPTAM 研究的结果。
J Clin Oncol. 2019 Mar 10;37(8):636-646. doi: 10.1200/JCO.18.00307. Epub 2019 Jan 24.
3
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.他莫昔芬及其代谢物(endoxifen)的临床药代动力学和药物遗传学。
Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536. doi: 10.1080/17512433.2019.1610390. Epub 2019 Apr 30.
4
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.细胞色素P450 2D6（CYP2D6）基因型和4-羟基他莫昔芬（endoxifen）引导的他莫昔芬剂量递增可提高血清中endoxifen浓度，且不增加副作用。
Breast Cancer Res Treat. 2015 Oct;153(3):583-90. doi: 10.1007/s10549-015-3562-5. Epub 2015 Sep 14.
5
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.对于CYP2D6活性降低的患者，增加他莫昔芬剂量可使4-羟基他莫昔芬浓度正常化且不增加毒性。
Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.
6
CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.CYP2D6 和他莫昔芬治疗中的内消旋体：纪念大卫 A.弗洛克哈特。
Clin Pharmacol Ther. 2018 May;103(5):755-757. doi: 10.1002/cpt.1039. Epub 2018 Feb 23.
7
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.乳腺癌的个体化医学：他莫昔芬、依西美坦和 CYP2D6 在临床实践中的应用。
Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.
8
Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.使用干血斑来测定他莫昔芬和内昔芬的血清浓度。
Breast Cancer Res Treat. 2014 Jul;146(1):137-44. doi: 10.1007/s10549-014-2999-2. Epub 2014 May 25.
9
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.利用他莫昔芬和依西美坦的药代动力学模型，确定导致乳腺癌患者治疗浓度不足的因素。
Clin Pharmacokinet. 2018 Feb;57(2):229-242. doi: 10.1007/s40262-017-0555-z.
10
Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.调整早期乳腺癌且细胞色素P450 2D6代谢不良者的他莫昔芬剂量。
Breast. 2014 Aug;23(4):400-6. doi: 10.1016/j.breast.2014.02.008. Epub 2014 Mar 29.

引用本文的文献

1
Effects of tamoxifen on cognitive function in patients with primary breast cancer.他莫昔芬对原发性乳腺癌患者认知功能的影响。
Br J Cancer. 2025 Feb;132(2):180-187. doi: 10.1038/s41416-024-02914-1. Epub 2024 Nov 26.
2
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?他莫昔芬剂量降级：降低不良反应的有效策略？
Drugs. 2024 Apr;84(4):385-401. doi: 10.1007/s40265-024-02010-x. Epub 2024 Mar 14.
3
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
他莫昔芬在非转移性乳腺癌老年患者中的药代动力学和药效学。
Breast Cancer Res Treat. 2023 Jun;199(3):471-478. doi: 10.1007/s10549-023-06925-z. Epub 2023 Apr 17.
4
The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer.依西美坦治疗对原发性乳腺癌患者内分泌副作用的影响。
ESMO Open. 2023 Feb;8(1):100786. doi: 10.1016/j.esmoop.2023.100786. Epub 2023 Feb 6.
5
Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.影响乳腺癌患者体内终末氧化代谢物浓度个体间变异性的因素：来自前瞻性 TOTAM 试验的结果。
Breast Cancer Res Treat. 2022 Aug;195(1):65-74. doi: 10.1007/s10549-022-06643-y. Epub 2022 Jul 16.
6
(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study.（Z）-依西美坦与乳腺癌早期复发：巴西一项前瞻性研究的探索性分析
J Pers Med. 2022 Mar 22;12(4):511. doi: 10.3390/jpm12040511.
7
Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial.治疗药物监测指导早期乳腺癌患者辅助他莫昔芬剂量：来自前瞻性 TOTAM 试验的成本效益分析。
Clin Drug Investig. 2022 Feb;42(2):163-175. doi: 10.1007/s40261-021-01114-6. Epub 2022 Jan 12.
8
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.他莫昔芬精准给药的依西美坦血药浓度监测：激素敏感型乳腺癌患者可行。
Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17.
9
Precision Dosing of Targeted Therapies Is Ready for Prime Time.精准靶向治疗的剂量调整已准备好进入黄金时代。
Clin Cancer Res. 2021 Dec 15;27(24):6644-6652. doi: 10.1158/1078-0432.CCR-20-4555. Epub 2021 Sep 21.
10
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups.通过计算治疗模拟评估不同生物地理群体乳腺癌患者个性化他莫昔芬给药的必要性。
Cancers (Basel). 2021 May 18;13(10):2432. doi: 10.3390/cancers13102432.